IKNA vs. TSBX, ELUT, ATRA, TIL, DTIL, GNTA, ENTX, CDTX, LENZ, and ALGS
Should you be buying Ikena Oncology stock or one of its competitors? The main competitors of Ikena Oncology include Turnstone Biologics (TSBX), Elutia (ELUT), Atara Biotherapeutics (ATRA), Instil Bio (TIL), Precision BioSciences (DTIL), Genenta Science (GNTA), Entera Bio (ENTX), Cidara Therapeutics (CDTX), LENZ Therapeutics (LENZ), and Aligos Therapeutics (ALGS). These companies are all part of the "biological products, except diagnostic" industry.
Turnstone Biologics (NASDAQ:TSBX) and Ikena Oncology (NASDAQ:IKNA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, community ranking, risk, valuation, analyst recommendations, media sentiment and institutional ownership.
Turnstone Biologics has higher revenue and earnings than Ikena Oncology.
Ikena Oncology's return on equity of 0.00% beat Turnstone Biologics' return on equity.
Ikena Oncology received 24 more outperform votes than Turnstone Biologics when rated by MarketBeat users. Likewise, 59.09% of users gave Ikena Oncology an outperform vote while only 50.00% of users gave Turnstone Biologics an outperform vote.
Turnstone Biologics presently has a consensus price target of $19.00, indicating a potential upside of 495.61%. Ikena Oncology has a consensus price target of $9.50, indicating a potential upside of 608.96%. Given Turnstone Biologics' stronger consensus rating and higher possible upside, analysts clearly believe Ikena Oncology is more favorable than Turnstone Biologics.
52.5% of Turnstone Biologics shares are held by institutional investors. Comparatively, 75.0% of Ikena Oncology shares are held by institutional investors. 6.0% of Ikena Oncology shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
In the previous week, Turnstone Biologics had 2 more articles in the media than Ikena Oncology. MarketBeat recorded 2 mentions for Turnstone Biologics and 0 mentions for Ikena Oncology. Ikena Oncology's average media sentiment score of 0.30 beat Turnstone Biologics' score of 0.00 indicating that Turnstone Biologics is being referred to more favorably in the media.
Summary
Ikena Oncology beats Turnstone Biologics on 9 of the 14 factors compared between the two stocks.
Get Ikena Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for IKNA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IKNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ikena Oncology Competitors List
Related Companies and Tools
